The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats

Neuroscience

Volumn 290, Issue , 2015, Pages 552-560

  Tan, X ^a,b   Chen, Y ^a,b   Li, J ^c   Li, X ^a,b   Miao, Z ^b   Xin, N ^a,b   Zhu, J ^a   Ge, W ^a   Feng, Y ^d   Xu, X ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c Suzhou Kowloon Hospital Affiliated with Shanghai Jiao Tong University School of Medicine   (China)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cdk5; Hypoxia ischemia injury; P35; P35 mimetic peptide

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 5; GLUCOCORTICOID RECEPTOR; NEUROPROTECTIVE AGENT; P5 TAT PEPTIDE; PROTEIN P25; PROTEIN P35; PROTEIN P39; TAU PROTEIN; UNCLASSIFIED DRUG; CASP3 PROTEIN, RAT; CDK5 ACTIVATOR P39; CDK5 PROTEIN, RAT; CDK5R1 PROTEIN, RAT; MAPT PROTEIN, RAT; NERVE PROTEIN; PHOSPHOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; NEUROPROTECTION; NEWBORN; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; HYPOXIA-ISCHEMIA, BRAIN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CASPASE 3; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; HYPOXIA-ISCHEMIA, BRAIN; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; RECOVERY OF FUNCTION; TAU PROTEINS;

EID: 84923084032     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.01.054     Document Type: Article

References (28)

1. Barros-Minones L., Martin-de-Saavedra D., Perez-Alvarez S., Orejana L., Suquia V., Goni-Allo B., Hervias I., Lopez M.G., Jordan J., Aguirre N., Puerta E. Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate. Biochim Biophys Acta 2013, 1832:705-717.
2. Behl C. Effects of glucocorticoids on oxidative stress-induced hippocampal cell death: implications for the pathogenesis of Alzheimer's disease. Exp Gerontol 1998, 33:689-696.
3. Bona E., Johansson B.B., Hagberg H. Sensorimotor function and neuropathology five to six weeks after hypoxia-ischemia in seven-day-old rats. Pediatr Res 1997, 42:678-683.
4. Cheung Z.H., Fu A.K., Ip N.Y. Synaptic roles of Cdk5: implications in higher cognitive functions and neurodegenerative diseases. Neuron 2006, 50:13-18.
5. Cheung Z.H., Ip N.Y. Cdk5: mediator of neuronal death and survival. Neurosci Lett 2004, 361:47-51.
6. Dhariwala F.A., Rajadhyaksha M.S. An unusual member of the Cdk family: Cdk5. Cell Mol Neurobiol 2008, 28:351-369.
7. Gu Q., Zhai L., Feng X., Chen J., Miao Z., Ren L., Qian X., Yu J., Li Y., Xu X., Liu C.F. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int 2013, 63:535-540.
8. Hayashi T., Warita H., Abe K., Itoyama Y. Expression of cyclin-dependent kinase 5 and its activator p35 in rat brain after middle cerebral artery occlusion. Neurosci Lett 1999, 265:37-40.
9. Jayapalan S., Natarajan J. The role of CDK5 and GSK3B kinases in hyperphosphorylation of microtubule associated protein tau (MAPT) in Alzheimer's disease. Bioinformation 2013, 9:1023-1030.
10. Julien J.P., Mushynski W.E. Neurofilaments in health and disease. Prog Nucl Acid Res Mol Biol 1998, 61:1-23.
11. Kino T., Ichijo T., Amin N.D., Kesavapany S., Wang Y., Kim N., Rao S., Player A., Zheng Y.L., Garabedian M.J., Kawasaki E., Pant H.C., Chrousos G.P. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol 2007, 21:1552-1568.
12. Love S. Neuronal expression of cell cycle-related proteins after brain ischaemia in man. Neurosci Lett 2003, 353:29-32.
13. O'Hare M.J., Kushwaha N., Zhang Y., Aleyasin H., Callaghan S.M., Slack R.S., Albert P.R., Vincent I., Park D.S. Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 2005, 25:8954-8966.
14. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
15. Pereira L.O., Arteni N.S., Petersen R.C., da Rocha A.P., Achaval M., Netto C.A. Effects of daily environmental enrichment on memory deficits and brain injury following neonatal hypoxia-ischemia in the rat. Neurobiol Learn Mem 2007, 87:101-108.
16. Rashidian J., Iyirhiaro G., Aleyasin H., Rios M., Vincent I., Callaghan S., Bland R.J., Slack R.S., During M.J., Park D.S. Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo. Proc Natl Acad Sci U S A 2005, 102:14080-14085.
17. Rashidian J., Rousseaux M.W., Venderova K., Qu D., Callaghan S.M., Phillips M., Bland R.J., During M.J., Mao Z., Slack R.S., Park D.S. Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo. J Neurosci 2009, 29:12497-12505.
18. Slevin M., Krupinski J. Cyclin-dependent kinase-5 targeting for ischaemic stroke. Curr Opin Pharmacol 2009, 9:119-124.
19. Tang D., Wang J.H. Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators. Prog Cell Cycle Res 1996, 2:205-216.
20. Tsai L.H., Delalle I., Caviness V.S., Chae T., Harlow E. P35 is a neural-specific regulatory subunit of cyclin-dependent kinase-5. Nature 1994, 371:419-423.
21. Wang J., Liu S., Fu Y., Wang J.H., Lu Y. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat Neurosci 2003, 6:1039-1047.
22. Wen Y., Yang S.H., Liu R., Perez E.J., Brun-Zinkernagel A.M., Koulen P., Simpkins J.W. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Bba-Mol Basis Dis 2007, 1772:473-483.
23. Xu X.S., Chua C.C., Gao F.P., Chua K.W., Wang H., Hamdy R.C., Chua B.H.L. Neuroprotective effect of humanin on cerebral ischemia/reperfusion injury is mediated by a PI3K/Akt pathway. Brain Res 2008, 1227:12-18.
24. Yin D., Zhou C., Kusaka I., Calvert J.W., Parent A.D., Nanda A., Zhang J.H. Inhibition of apoptosis by hyperbaric oxygen in a rat focal cerebral ischemic model. J Cereb Blood Flow Metab 2003, 23:855-864.
25. Zheng G.Q., Wang X.M., Wang Y., Wang X.T. Tau as a potential novel therapeutic target in ischemic stroke. J Cell Biochem 2010, 109:26-29.
26. Zheng Y.L., Amin N.D., Hu Y.F., Rudrabhatla P., Shukla V., Kanungo J., Kesavapany S., Grant P., Albers W., Pant H.C. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol Chem 2010, 285:34202-34212.
27. Zheng Y.L., Amin N.D., Hu Y.F., Rudrabhatla P., Shukla V., Kanungo J., Kesavapany S., Grant P., Albers W., Pant H.C. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol Chem 2010, 285:34202-34212.
28. Zhou Y., Bhatia I., Cai Z., He Q.Y., Cheung P.T., Chiu J.F. Proteomic analysis of neonatal mouse brain: evidence for hypoxia- and ischemia-induced dephosphorylation of collapsin response mediator proteins. J Proteome Res 2008, 7:2507-2515.